- Press Release -

Rockville, Md. The global colorectal cancer diagnostics market is set to expand at an 8.5% CAGR and pass US$ 2 Bn by 2022, according to Fact.MR, as one of the world's most common cancers drives steady demand for testing. Colorectal cancer ranks as the third most frequent malignancy worldwide, and rising case numbers, especially across developed economies, keep pulling diagnostic volumes higher.

North America carries the market, FOB tests lead by type, and hospital-associated labs handle most testing. Even as death rates ease on the back of awareness work by bodies such as the American Cancer Society, better tests and broader screening keep the market growing.

Tests, Settings and Regions

FOB remains the most widely adopted test and holds the largest revenue, followed by CTC tests. The sharper growth belongs to immunochemistry tests, which post the highest CAGR, while BRAF testing stays the smallest contributor. By setting, hospital-associated labs are the leading end user and approach US$ 1 Bn by 2022, independent diagnostic laboratories rank second, and cancer research institutes grow the fastest.

North America stays the most lucrative region and is set to pass US$ 800 Mn by 2022, Asia Pacific excluding Japan grows quickest, and the Middle East and Africa remain subdued.

Screening and Awareness Drive Demand

The market's momentum rests on earlier and wider detection. New diagnostic tests, greater uptake of diagnosis-linked therapies, and public and private screening initiatives are pulling demand forward, while unmet need across emerging economies leaves room for further growth. Patient reluctance and low awareness in remote regions remain the main brakes on the market.

Suppliers and Their Playbook

The field brings together sequencing, molecular diagnostics and liquid biopsy specialists.

• Illumina, Inc., Foundation Medicine, Inc., Sysmex Corporation, Cancer Genetics, Inc., Danaher Corporation, Biocept, Inc, Pathway Genomics Corporation, Rosetta Genomics, Epigenomics AG, and Exact Science Corporation are among the key players in the report.

Reading the Market for Decisions

For diagnostics firms, growth favours immunochemistry and screening-oriented tests. Investors get a market with a firm clinical tailwind and a healthy CAGR. Procurement and lab teams can plan around hospital labs leading demand, FOB carrying volume, and North America offering the largest opportunity through 2022.

About the Report

Fact.MR's study covers the global colorectal cancer diagnostics market for the 2017 to 2022 forecast period, with segmentation by test type, end user and region. It sizes each segment, maps the competitive field, and weighs the clinical and awareness forces shaping demand. Further detail is available in the colorectal cancer diagnostics market report.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. The firm is known for its syndicated research, custom research and consulting solutions, helping clients make decisions on demand, competition, investment, procurement and future growth.